Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/31206
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2018-06-21T06:45:12Z-
dc.date.available2018-06-21T06:45:12Z-
dc.date.issued2017-
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/31206-
dc.descriptionB.SC.(HONS)NURSINGen_GB
dc.description.abstractFor the purpose of this dissertation, a comparative account between new oral anticoagulants and Warfarin was conducted in order to identify which class of drugs is safer and more effective in reducing cerebrovascular accidents in patients having non-valvular atrial fibrillation. For this reason the following clinical inquiry was identified: “In adult patients with nonvalvular atrial fibrillation, are non-vitamin K inhibitors/New Oral Anticoagulants (Dabigatran, Apixaban, Edoxaban and Rivaroxaban) more safe and effective than Warfarin (a vitamin K inhibitor) in reducing the risk of cerebrovascular accidents?” 1. Population/P: People with Nonvalvular Atrial Fibrillation/NVAF. 2. Intervention/I: Non-Vitamin K Inhibitors/New Oral Anticoagulants/NOACs. 3. Comparison/C: Warfarin. 4. Outcome/O: Reduction in Cerebrovascular Accidents/CVA. Given the comparative nature of the inquiry, selected studies had to compare new oral anticoagulants with Warfarin, having the following criteria: Inclusion Criteria: participants signed an informed consent; postmenopausal/ sterile/abstinent participants; atrial fibrillation individuals aged >18 years; subjects may be diagnosed with chronic kidney disease; studies published after 2005. Exclusion Criteria: individuals with liver disease and/or having contraindications to anticoagulants; anaemic individuals; pregnant/breast-feeding mothers; studies incorporating haemorrhagic individuals. The final outcome of the search yielded a total of nine articles (four meta-analysis and systematic reviews and five meta-analysis of randomised controlled trials). Each article was appraised using the Oxford critical appraisal skills program tool. The main results show that new oral anticoagulants substantially decreased cerebrovascular accidents, systemic embolic events, intracranial bleeding and mortality; with their only downfall being an increased incidence of gastrointestinal bleeding. For these reasons, several implications for practice, management, education and research; including the importance of long-term self-monitoring of blood pressure (shown to reduce hospitalisations), assessment for creatinine clearance via blood investigations, importance of pedagogy and the need for further research in identifying new oral anticoagulant antidotes were recommended.en_GB
dc.language.isoenen_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectCerebrovascular disease -- Maltaen_GB
dc.subjectAnticoagulants (Medicine) -- Maltaen_GB
dc.subjectWarfarin -- Maltaen_GB
dc.titleNOACs vs. Warfarin in reducing CVA episodes in patients having NVAFen_GB
dc.typebachelorThesisen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.publisher.institutionUniversity of Maltaen_GB
dc.publisher.departmentFaculty of Health Sciences. Department of Nursingen_GB
dc.description.reviewedN/Aen_GB
dc.contributor.creatorBaldacchino, Clyde-
Appears in Collections:Dissertations - FacHSc - 2017
Dissertations - FacHScNur - 2017

Files in This Item:
File Description SizeFormat 
17BSNR06.pdf
  Restricted Access
1.42 MBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.